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Summary
Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-
Hodgkin lymphoma (B-NHL) in children and adolescents and is charac-
terised by a MYC translocation and rapid cell turnover. Intensive
chemotherapeutic regimens have been developed in recent decades, includ-
ing the lymphomes malins B (LMB) protocol, which have resulted in a sur-
vival rate in excess of 90%. Recent clinical trials have focused on
immunochemotherapy, with the addition of rituximab to chemotherapeutic
backbones, showing encouraging results. Despite these advances, relapse
and refractory disease occurs in up to 10% of patients and salvage options
for these carry a dismal prognosis. Efforts to better understand the molecu-
lar and functional characteristics driving relapse and refractory disease may
help improve this prognosis. This study has established a paediatric BL
patient-derived xenograft (PDX) resource which captures and maintains
tumour heterogeneity, may be used to better characterise tumours and
identify cell populations responsible for therapy resistance.
Keywords: Burkitt lymphoma, patient derived xenograft, relapse, B-cell
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B-cell non-Hodgkin lymphoma (B-NHL) represents the most
common subtype of NHL in childhood and adolescence,
accounting for up to 60% of all newly diagnosed lym-
phomas.1,2 Burkitt lymphoma (BL) alone accounts for almost
two-thirds of B-NHL in children and adolescents and is most
prominent in the 0–14 age group.3 The defining characteris-
tic of BL is a translocation of the MYC oncogene on chro-
mosome 8 with the immunoglobulin genes on chromosomes
14, 22 or 2 and it presents in advanced form (stage III/IV) in
70% of patients.4,5 In the modern era, all aggressive mature
paediatric B-NHL patients receive the same treatment regi-
mens and outcomes have improved dramatically in recent
decades, with trials showing survival of approximately 90%.6–
8 The clinical focus has been on establishing risk-stratifica-
tion to reduce the acute and long-term toxicities associated
with therapy for those patients with a favourable prognosis.
Recent clinical trials in paediatric B-NHL involve the combi-
nation of rituximab, an anti CD20 antibody, with a
chemotherapeutic backbone, based on the rationale that the
CD20 antigen is present in over 98% of cases of paediatric
mature B-NHL.9 The addition of rituximab to a modified
lymphomes malins B (LMB) chemotherapy regimen has
recently been evaluated in the Inter-B-NHL Ritux study with
results showing prolonged event-free survival and overall sur-
vival among children and adolescents with high-grade, high-
risk, mature B-NHL.10 Despite these developments, prognosis
in refractory and relapse cases remains dismal, with few
options to successfully salvage patients and the two-year
overall survival rate with chemoimmunotherapy reported as
15–33%.11,12 The cellular population(s) responsible for prop-
agating refractory/relapsed disease have not yet been identi-
fied, largely due to the lack of suitable model systems.13
Patient-derived xenograft (PDX) models have evolved as a
powerful preclinical tool capable of bridging the gap between
established cell lines and primary tumour samples. PDXs better
maintain the heterogeneity of patient tumours and hence allow
for a more clinically relevant examination of tumour evolution,
response to therapy and development of chemo-resistance.
Despite a relatively homogeneous histological appearance, stud-
ies have demonstrated both inter- (across patients) and intra-
(within tumours) heterogeneity in BL.14,15 Love et al.16 reported
considerable heterogeneity in the number of mutated genes
across samples: out of a total of 70 mutated genes, the range of
mutations in the sample cohort was 2 to 16. Model systems such
as PDXs which capture the genetic and functional heterogeneity
of primary paediatric BL will be necessary to identify targeted
therapies for individual patients, as well as to decipher the clo-
nal dynamics that lead to resistant disease in 5–10% of patients.5
PDX models of B-cell lymphoma exist, although those pub-
lished have been developed from adult tumours and consist
mainly of the Diffuse Large B-cell Lymphoma (DLBCL) sub-
type, the most common B-cell lymphoma in the adult popula-
tion, and their applicability to paediatric B-NHL is limited.17
This paper documents, to our knowledge, the establishment of
the largest PDX resource for paediatric BL, providing a valuable
tool to characterise tumours and better understand the func-
tional and molecular characteristics of this tumour type.
Materials and methods
Primary patient samples
Paediatric B-NHL primary patient samples were obtained
from redundant tissue taken at the time of the diagnostic
biopsy, following informed consent on enrolment of patients
to the Inter B-NHL Ritux clinical trial or following local eth-
ical approval (Research Ethics Committee Reference: 07/
q0104/16). One patient sample was obtained with informed
consent from the Newcastle Haematology Biobank (Research
Ethics Committee Reference: 07/H0906/109+5). One patient
biopsy (to generate PDX6) was obtained at relapse from a
drained peritoneal effusion of a patient refractory to ICE
(ifosfamide, carboplatin, etoposide) therapy.
Patient sample processing
Mononuclear cells (MNCs) were isolated from pleural effu-
sion, peripheral blood or bone marrow by gradient centrifu-
gation over LymphoprepTM (STEMCELL Technologies,
Cambridge, UK). Tumour samples from solid biopsies
underwent mechanical disaggregation by passing cells
through a 70 lmol/l nylon cell strainer (BD Falcon, Erem-
bodegem, Belgium) using the plunger of a 5 ml syringe (BD
Plastipak, BD Falcon), applying light to medium mechanical
force. Isolated MNCs were washed once with phosphate-buf-
fered saline (PBS, ThermoFisher, Waltham, MA, USA) before
injection into mice or further analysis.
Mice
JAXTM NSG Mice (NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ) were
obtained from Charles River, Margate, UK and housed in
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individually ventilated cages (IVCs) under sterile pathogen-
free (spf) conditions at the University of Cambridge under
project licence numbers 80/2630 (2014–2017) and P4DBEFF63
(2018–2020). Additional animals in Newcastle were housed
and used under project licence 60/4552 (2013–2018).
Tumour growth in NSG mice
Isolated MNCs (5 9 106) were suspended in 200 ll of PBS
and mixed with 200 ll of matrigel (Corning, Flintshire, UK)
before 300 ll of suspension was injected subcutaneously
(SC) or intraperitoneally (IP) into NSG mice. Once tumours
reached the maximum regulatory allowed size of 12 cm
(15 cm in 10% of cases) in any one direction, animals were
culled and the tumour removed and disaggregated by passing
cells through a 70 lmol/l nylon cell strainer (BD Falcon).
For serial passage, cells (1 9 105) were resuspended in matri-
gel as described and re-injected.
Fluorescence in situ hybridization
Fluorescent in situ hybridization (FISH) was carried out to
determine the presence of the MYC translocation. Single-cell
suspensions were collected by centrifugation at 200 g for
5 min and resuspended in Carbonyl’s Fixative (3:1 methanol:
glacial acetic acid). FISH was performed using a Vysis LSI
IGH/MYC/CEP 8 Tri-Color Dual Fusion Probe Kit (Abbott
Diagnostics, Maidenhead, UK). Results were reported as the
percentage of cells positive for IGH-–MYC rearrangement as
well as the signal pattern.
Tumour histology
Following extraction of tumours, either the whole tumour or
a representative biopsy was immediately placed in 10% neu-
tral-buffered formalin (Sigma-Aldrich, Gillingham, UK).
After 24 h the tumour was removed and placed in 70% etha-
nol/PBS. Tumours were embedded in paraffin before sections
were cut and stained with haematoxylin and eosin using
standard procedures. Sections were analysed by a
histopathologist at the Department of Pathology, University
of Cambridge and images captured at 209 magnification.
Flow cytometry
Cells were washed with PBS and collected by centrifugation at
250 g for 5 min before resuspension in flow cytometry buffer
[PBS, 005% Bovine Serum Albumin (ThermoFisher, Wal-
tham, MA, USA)] at a concentration of 1 9 106 cells/ml. Cell
suspension (100 ll) was added to each well of a 96-well plate
and stained with the following: murine phycoerythrin, fluo-
rescein isothiocyanate, allophycocyanin or cyanine 7 (Cy7)—
conjugated antibodies: CD9, CD10, CD19, CD20, CD21,
CD24, CD27, CD34, CD38, CD40, CD44, CD45, CD49d,
CD49f, CD59, CD90, CD117, CD133, CD184, ABCG2 (BD
Biosciences, Erembodegem, Belgium). After staining (40 min
at 4°C, 1:100), cells were washed in PBS and resuspended in
2 ml of flow cytometry buffer before immediate analysis on a
BD Accuri C6 or a LSR Fortessa Flow Cytometer. At least
10 000 events were recorded and data analysed with FlowJo
v9.1 (BD, Erembodegem, Belgium). The lymphocyte popula-
tion was selected and expression levels determined based on
gates set using unstained control.
Whole genome sequencing
DNA was extracted with a DNeasy Blood & Tissue Kit (Qia-
gen, Manchester, UK) and whole genome sequencing (WGS)
was performed on the Illumina Novaseq 6000 (Cambridge,
UK). Sequencing reads in FASTQ format were quality-checked
with FastQC (version 0.11.9; Babraham Bioinformatics, Cam-
bridge, UK, https://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc/) and mapped to the hg38 human genome
assembly using BWA (07.17-4, Heng Li, Boston, MA, USA,
https://github.com/lh3/bwa) with the ‘-M’ compatibility
option. BAM files were coordinate-sorted with Samtools
(110-3, Genome Research Limited, Saffron Walden, UK,
http://www.htslib.org/). Duplicate marking and base quality
score recalibration was performed with the GATK suite
(41.40, Broad Institute, Cambridge, MA, USA, https://
gatk.broadinstitute.org/). Single nucleotide variants (SNVs)
and small insertions and deletions (indels) were called and fil-
tered using GATK Mutect2 and FilterMutectCalls with recom-
mended parameters, and annotated with SnpEff (43, Pablo
Cingolani, https://pcingola.github.io/SnpEff/). To compile a
list of genes with possible involvement in BL pathophysiology,
we took the union of: COSMIC (Wellcome Sanger Institute,
Hinxton, UK, https://cancer.sanger.ac.uk/cosmic) ‘Genes with
mutations’ for BL histology, genes mutated in the validation
cohort of Grande et al.18 and recurrently mutated genes from
the Love et al.16 cohort, yielding 4 272 genes. To enrich for
functional variants, intergenic, intronic, and synonymous
SNVs were excluded. To avoid including potential germline
variants, variant allele frequencies (VAFs) in the range (0,
097) were included. Data visualisation and statistical analysis
was performed in R: The R Project for Statistical Computing
(https://www.r-project.org/).
RT-qPCR quantification of gene expression
All kits were used according to the manufacturer’s instruc-
tions. To compare gene expression levels, total RNA was iso-
lated with the RNeasy Plus Mini Kit (Qiagen) before RNA
(1 lg) was reverse transcribed using the ProtoScript II First
Strand cDNA Synthesis Kit (NEB, Ipswich, MA, USA). RT
reactions were diluted (1:10) and 10 ng equivalent (to input
RNA amount) was used as the template DNA for quantita-
tive polymerase chain reaction (qPCR) using Power SYBR
Green PCR Master Mix (ThermoFisher) with standard reac-
tion conditions on the QuantStudioTM 6 Flex Real-Time
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PCR System (ThermoFisher). PCR was carried out using pri-
mers specific to the following genes: MYC FWD 50-GGCT
CCTGGCAAAAGGTCA-30, MYC R 50-CTGCGTAGTTGT
GCTGATGT-30; BCL2 FWD 50-GGTGGGGTCATGTGTG
TGG-30, BCL2 R 50-CGGTTCAGGTACTCAGTCATCC-30;
BCL6 FWD 50-ACACATCTCGGCTCAATTTGC-30, BCL6 R
50-AGTGTCCACAACATGCTCCAT-30; GNA13 FWD 50-CCC
AAGGAATGGTGGAAACAA-30, GNA13 R 50-ACCCAGTT-
GAAATTCTCGACG-30; ID3 FWD 50-GAGAGGCACTCAG
CTTAGCC-30, ID3 R 50-TCCTTTTGTCGTTGGAGATGAC-
30; TCF3 FWD 50-CCGACTCCTACAGTGGGCTA-30, TCF3
R 50-CGCTGACGTGTTCTCCTCG-30; PIM1 FWD 50-GAG
AAGGACCGGATTTCCGAC-30, PIM1 R 50-CAGTCCAG-
GAGCCTAATGACG-30; ARID1A FWD 50-CCAGCAGAA
CTCTCACGACC-30, ARID1A R 50-CTGAGCGAAGGAC
GAAGACG-30; CDK4 FWD 50-ATGGCTACCTCTCGATAT-
GAGC-30, CDK4 R 50-CATTGGGGACTCTCACACTCT-30;
CDC7 FWD 50-AGTGCCTAACAGTGGCTGG-30, CDC7 R
50-CACGGTGAACAATACCAAACTGA-30; GAPDH FWD 50-
GGAGCGAGATCCCTCCAAAAT-30, GAPDH R 50-GGC
TGTTGTCATACTTCTCATGG-30; PTEN FWD 50-TTTGAA-
GACCATAACCCACCAC-30, PTEN R 50-ATTACACCAG
TTCGTCCCTTTC-30; PAX5 FWD 50-ACTTGCTCATCAA
GGTGTCAG-30, PAX5 R 50-TCCTCCAATTACCCCAGGC
TT-30; MTOR FWD 50-TCCGAGAGATGAGTCAAGAGG-30,
MTOR R 50-CACCTTCCACTCCTATGAGGC-30; SMARCA4
FWD 50-GACCAGCACTCCCAAGGTTAC-30, SMARCA4 R
50-CTGGCCCGGAAGACATCTG-30. Data were analysed
using the double delta Ct (ΔΔCt) method conducted with
normalization to GAPDH (ΔCt) before relative expression
level comparison to the control sample (ΔΔCt). All qPCR
reactions were performed in technical triplicates.
Results
Establishment of PDX models from paediatric Burkitt
lymphoma biopsy material
Samples from paediatric patients diagnosed with BL were
taken from various sites including tumour biopsy (n = 1),
Fig 1. Tumour cell characteristics are maintained following engraftment in NSG mice. (A) Mononuclear cells (MNCs) were isolated from a
patient pleural effusion sample and resuspended in phosphate-buffered saline (PBS) before injection via the subcutaneous (left) or intraperitoneal
route (right). (B) The lymphocyte population of patient sample 3 pleural effusion was analysed before and after gradient centrifugation and isola-
tion of MNCs, resulting in enrichment of lymphocytes. (C) Isolated MNCs from patient sample 3 were analysed for surface antigen expression
before and after engraftment in a mouse [patient-derived xenograft (PDX) 1]. (D) Overview of surface antigen expression before and after
engraftment. Heatmap represents percentage surface antigen expression as determined by flow cytometry. (E) The tumourigenic cell population
in a peripheral blood sample (patient sample 4, PDX2) and a bone marrow sample (patient sample 9, PDX3) were identified based on expression
of CD20. (F) MNCs from initial peripheral blood biopsy sample of patient sample 4 and after passage 1 (PDX2) were analysed for expression of
surface antigens CD117 and ABCG2. [Colour figure can be viewed at wileyonlinelibrary.com]
Table I. Details of biopsy site, diagnosis, disease stage and engraftment status for each patient sample and the resulting patient-derived xenograft
(PDX).
Sample number Patient Biopsy site Diagnosis Stage
Engraftment
success PDX formed
1 1 Needle biopsy of
abdominal mass
Burkitt lymphoma III No
2 1 Bone marrow Burkitt lymphoma III No
3 2 Pleural effusion Burkitt lymphoma III Yes PDX1
4 3 Peripheral blood Burkitt lymphoma/
leukaemia with CNS involvement
IV Yes PDX2
5 3 Bone marrow Burkitt lymphoma/
leukaemia with CNS involvement
IV No
6 4 Peripheral blood Burkitt lymphoma IV No
7 4 Bone marrow Burkitt lymphoma IV No
8 5 Bone marrow Burkitt lymphoma/leukaemia IV No
9 6 Bone marrow Burkitt lymphoma III Yes PDX3
10 7 Pleural effusion Burkitt lymphoma III Yes PDX4
11 8 Pleural effusion Burkitt lymphoma IV Yes PDX5
12 9 Peripheral blood Burkitt lymphoma IV No
13 9 Bone marrow Burkitt lymphoma IV No
14 10 Peritoneal effusion Burkitt lymphoma Relapse Yes PDX6
All samples were received following procedure to obtain diagnostic biopsies prior to treatment except for sample 14 from patient 10 that was
taken when the patient had relapsed and was refractory to therapy with ICE (ifosfamide, carboplatin, etoposide). CNS, central nervous system.
S. Forde et al.
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peritoneal fluid (n = 1), pleural effusion (n = 3), bone mar-
row (n = 6) and peripheral blood (n = 3) (Table I). In total,
14 samples were obtained from 10 patients with six samples
resulting in successful engraftment; an engraftment rate of
43%. The primary method of engraftment was subcutaneous
(SC) injection of mononuclear cells (MNCs) with matrigel,
although cells were also injected in separate mice intraperi-
toneally (IP) and intravenously (IV) when sufficient numbers
were available. Of note, IV injection was attempted for all
tumour samples from peripheral blood and bone marrow
but no engraftment of Burkitt cells in the peripheral blood
of mice was detected. In all cases where SC injection resulted
in tumour engraftment, IP injection of cells from the same
sample also successfully engrafted (Fig 1A). Pleural effusion
samples engrafted most consistently with 3/3 forming a PDX
while 0/1 solid tumour, 1/1 peritoneal fluid, 1/3 peripheral
blood and 1/6 bone marrow samples were successfully
engrafted. The only sample of peritoneal fluid, also the only
tumour from a relapse patient, was engrafted SC only and
formed a tumour.
Given that all but one biopsy sample were obtained in liq-
uid form from sites with potentially mixed cell populations,
non-tumour cells were initially depleted from all peripheral
blood, pleural effusion and bone marrow samples by gradient
centrifugation. This resulted in an enrichment of lympho-
cytes including the B-cell tumour population. For example,
lymphocytes increased from 5 to 55% of the cell population
of the pleural effusion (Fig 1B) after MNC isolation of
patient sample 3, the first sample to form a PDX. This
enriched lymphocyte population was CD10+CD20+, a
Fig 2. No new variants in Burkitt lymphoma (BL)-related genes emerged or were lost following expansion of a xenograft in NSG mice. Scatter
plot of variant allele frequencies in a patient BL tumour before and after first passage in a mouse. Individual points represent Single nucleotide
variants and small indels in genes previously reported to be mutated in BL; see Materials and methods for details. Mutated genes from the valida-
tion cohort of Grande et al.18 are highlighted. Blue line represents linear regression fit (F1,117 = 2 210, R
2 = 095, P = <22 9 1016). R2, adjusted
R-squared statistic. [Colour figure can be viewed at wileyonlinelibrary.com]
Fig 3. Tumour histological, molecular and surface expression features were maintained through passage in NSG mice. (A) Representative haema-
toxylin–eosin (H&E) images of patient-derived xenograft (PDX) tumours at passage 1 and 5 taken from all five PDX models (scale bar = 100 lm).
(B) fluorescence in situ hybridisation (FISH) analysis of tumour cells at passage 1 and 5 from all five PDX. A representative image of a 4’,6-di-
amidino-2-phenylindole (DAPI -stained nucleus is shown. Figures below the images represent the percentage of cells positive for the MYC translo-
cation (n = 100). Aqua (A) signal = centromere of chromosome 8, red (R) signal = MYC, green (G) signal = IgH, F = fusion. (C) Quantitative
real time- polymerase chain reaction (RT-qPCR) was carried out for a selection of 14 Burkitt lymphoma (BL) representative genes at passages 1
and 5 for all five PDX with cDNA from the Raji cell line as the control. (D) Detailed surface expression profiling of each PDX highlights the signif-
icant inter- and intratumour heterogeneity and maintenance from P1 to P5. Heatmap represents percentage surface antigen expression as deter-
mined by flow cytometry; white represents antigen not expressed in that PDX. [Colour figure can be viewed at wileyonlinelibrary.com]
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phenotype characteristic of Burkitt lymphoma cells (Fig 1C).
Importantly, the cell surface phenotype of the PDX1 cell
population after passage 1 was indistinguishable from that of
the lymphocyte population of the pleural effusion biopsy
sample from which it was derived (patient sample 3; Fig 1C,
D). PDX5, also derived from a pleural effusion sample,
showed similar maintenance of the lymphocyte cell surface
phenotype between biopsy and passage 1 (Fig 1D). PDX2
and PDX3 were derived from peripheral blood and bone
marrow patient samples, respectively, with a mixed popula-
tion of healthy and tumourigenic blood cells within the
biopsy samples (Fig 1E). Once the PDX had been established,
that is, tumours grew in the mice on first passage, 96% of
lymphocytes in PDX2 and 95% in PDX3 were CD20+, com-
pared to 84% and 42% of the total lymphocyte population,
respectively, in the original patient biopsies, suggesting that
tumour cells are selected in vivo (Fig 1D,E). Conversely, the
small population of CD117+ cells present in the starting
material for PDX2 was lost in the established graft, although
these cells were CD20 suggesting they were not tumour cells
(Fig 1F). However, a minor population of CD20+ABCG2+
cells was present in the initial biopsy and in the established
graft, suggesting that even minor cell populations within the
patient biopsy sample were maintained in the PDX on
engraftment (Fig 1F). PDX4 did not have spare biopsy mate-
rial available for analysis.
To investigate the maintenance of genetic intratumour
heterogeneity in the PDX model employed in this study,
WGS was performed on the PDX developed from a relapse
BL peritoneal fluid sample that had sufficient material both
at biopsy and after passage 1 (PDX6). Importantly, no new
variants in BL-related genes emerged or were lost following
expansion of the xenograft in vivo (Fig 2; Figure S1). Fur-
thermore, linear regression of VAFs before and after passage
yielded an adjusted R2 statistic of 095, indicating a good fit
(slope: 098, intercept: 003, P < 22 9 1016).
PDX models maintain their phenotypic, molecular and
histopathological features through passage
To validate that PDX models are a robust and reliable
resource that recapitulate the features of paediatric BL
through propagation in mice, tumours were monitored at
each passage. Histopathological analysis of each tumour after
passages 1 (P1) and 5 (P5) was performed showing mainte-
nance of high-grade lymphoma histology (Fig 3A). The char-
acteristic MYC translocation of BL was identified at diagnosis
for each patient and maintenance of the translocation signal
in all PDX cells was monitored through passage using FISH.
At P5, for all of the PDX (PDX1–5), the specific MYC
translocation was maintained in almost 100% of tumour cells
(Fig 3B). To determine if serial passage impacts the expres-
sion profile of tumours, expression profiling of genes associ-
ated with BL was conducted at P1 and P5. The coefficient of
determination between P1 and P5 for each PDX was greater
than 094, highlighting consistent expression levels of this
limited selection of genes at both passages (Fig 3C; Fig-
ure S2). Comparison with the original diagnostic material
was not possible, as there was insufficient material available.
Cell surface expression profiling between passages 1 and 5
also highlighted that all tumours faithfully maintained their
surface expression profile over passage. All five PDXs showed
strong expression of surface proteins characteristic of BL,
such as CD20+, while minor populations of tumour cells
were also maintained within each PDX, for example,
ABCG2+ cells (Fig 3D). This highlights the significant intra-
and intertumour heterogeneity within these PDX models
which was also maintained through multiple passage
(Fig 3D). The maintenance of precise surface expression pro-
files within each PDX, over five passages, highlights the exis-
tence of an intricate population equilibrium within the
individual tumours. Importantly, subpopulations that were
maintained through passage, at varying levels in the five
PDXs, included populations not commonly reported in BL
such as CD9+, CD90+, CD44+ and CD49D+ cells (Fig 3D).
PDXs can be used to mimic response to therapy in vivo
The mean number of days for the injected primary cells to
first produce palpable tumours when engrafted SC was 33
(range 28–48 days) with PDX3 from a bone marrow sample
having the longest engraftment time (Fig 4A). Once estab-
lished, passage 2 of each PDX led to the development of pal-
pable tumours more quickly (Fig 4A) and the total time
from injection to produce tumours of maximum allowed
size, according to UK guidelines, was largely consistent for
each PDX across passages, from P2 onwards (Fig 4B). The
ability of these PDX models to give rise to large, palpable
Fig 4. Established patient-derived xenograft (PDX) models respond to multiagent chemotherapy with PDX4 showing greatest resistance. (A) The
number of days for primary tumour samples to achieve initial engraftment (passage 1) and for subsequent PDXs to engraft at passage 2 was mon-
itored. Graph shows n = 1 for passage 1 and means and standard deviation for passage 2, n = 2. (B) The number of days from injection of cells
for PDX tumours to reach maximum size was monitored for PDXs at each passage. Graph shows means and standard deviation, n = 2. (C) The
impact of treatment on animal weight was monitored after chemotherapy and vehicle control administration and maximum percentage change in
weight recorded. (D) Chemotherapy was administered intraperitoneally to mice when tumours reached 400 mm3 in volume. Drug concentrations:
3 mg/kg doxorubicin, 15 mg/kg methotrexate, 025 mg/kg vincristine. Increased to 375 mg/kg doxorubicin, 1875 mg/kg methotrexate,
03125 mg/kg vincristine in PDX4. Treatment was repeated every 72 h and ceased when tumour volume reached 50 mm3. Graphs show tumour
volume measurements taken every day. Tumour volume was calculated using the modified ellipsoid formula 1/2(Length 9 Width2). [Colour fig-
ure can be viewed at wileyonlinelibrary.com]
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tumours within a relatively short timeframe provides an
excellent resource to conduct in vivo experiments and inves-
tigate patient-specific tumour characteristics, such as hetero-
geneity and response to therapy. Multi-agent chemotherapy
(doxorubicin, methotrexate and vincristine) was administered
every 72 h, once tumours reached a volume of 400 mm3.
Chemotherapy was stopped after a maximum of six doses
when tumours shrank to 50 mm3. Chemotherapy led to a
discrete but significant weight loss for all 5 PDX models
compared to vehicle-only controls (Fig 4C). In the case of
PDX 1, 2, 3 and 5, tumours responded to lower-dose
chemotherapy based on decreased tumour volumes (Fig 4D),
whereas PDX4 only showed a significant treatment response
upon administration of an increased concentration of multi-
agent chemotherapy.
Discussion
Survival rates in paediatric BL approach 90% but salvage
options in relapse and refractory disease remain very lim-
ited.5 It is necessary for us to develop a greater understand-
ing of the different populations within tumours to reduce
the use of toxic chemotherapy and to develop targeted thera-
pies for difficult-to-treat chemoresistant relapse and refrac-
tory cases. In evidence, studies have shown that personalised
therapeutic approaches designed according to PDX treatment
responses result in improved clinical outcomes.19 For adult
B-NHL, due to the genetic heterogeneity of tumours, several
different pathways leading to drug resistance have been iden-
tified and this is also likely the case for paediatric BL. Che-
moresistance in paediatric BL may, therefore, require the
development of personalised approaches to address patient-
to-patient genetic heterogeneity. In this study we have suc-
cessfully established PDX models of paediatric BL and
demonstrated their ability to faithfully maintain molecular
and phenotypic characteristics through multiple passages.
This ensures the model possesses a high level of clinical rele-
vance and can be used for identifying populations with
chemoresistance potential as well as to investigate the poten-
tial efficacy of targeted therapies.
Patients in this study presented with both BL and leukae-
mia and PDXs were mainly established from liquid biopsies
from peripheral blood, bone marrow, pleural effusion and
peritoneal fluid. The only solid biopsy sample included did
not lead to PDX establishment. An engraftment rate of 43%
was observed when considering all specimens received and
each of the engrafted PDX were successfully propagated by
long-term serial passage. This rate is comparable to that in
many other similar studies with one review of existing data
highlighting that engraftment rates typically vary between
23% and 75% depending on the tumour type20: A study of
adult B-NHL, including mainly mantle cell lymphoma
(MCL) and DLBCL, with one BL sample had a 67% success
rate for serial passage21 and a further study in DLBCL
reported a 32% success rate for serial passage.17
Pleural effusion samples had the highest engraftment rate
in this study, although one PDX developed from peripheral
blood and another from bone marrow via both the IP and
SC routes. In contrast, tumour growth was not observed,
independent of the site of origin, when engrafted IV. Given
these potential limitations, a key consideration when utilising
PDXs as a model for cancer is to determine how well they
represent the original patient disease. In this study, PDX
models established from pleural effusions showed a strong
phenotypic correlation with the biopsy material, likely
because there are fewer non-tumourigenic immune cells in
the pleural effusion compared to the peripheral blood and
bone marrow. The change in cell surface phenotype of the
lymphocyte population between the diagnostic biopsy and
the first passage for PDX established from peripheral blood
and bone marrow, is likely due to outgrowth of tumour cells
in the mouse with loss of infiltrating immune and other cells.
A number of further lines of evidence suggest that changes
did not occur to the tumour populations between the initial
biopsy and P1: All tumours were almost 100% MYC translo-
cation-positive after P1, matching reports of the original
biopsy samples and minor cell populations that were lost
from the biopsy sample were shown to be CD20 and hence,
most likely healthy immune cells that fell into the same for-
ward and side scatter gate as the BL cells. Insufficient biopsy
material meant detailed genomic analysis was not possible
for these PDX. However, PDX6 generated from the peri-
toneal fluid of a relapsed patient had sufficient pre-engraft-
ment and P1 material available for WGS. Analysis of
potential functional variants in 4 272 genes associated with
BL pathophysiology highlighted that no new variants in BL-
related genes emerged or were lost in the xenograft. Further-
more, linear regression analysis identified a strong relation-
ship between VAF before and after engraftment, suggesting
that the methodology used for the establishment of the PDX
models in this study did not introduce strong selection bias.
The stability of the genetic characteristics after engraftment
in this PDX is encouraging given that Schmitz et al. high-
lighted that in xenografted leukaemia, changes in copy num-
ber alterations emerged in the majority of cases during the
first passage in mice.22 Other studies have also shown the
persistence of tumour characteristics upon in vivo passage
including a study of MCL PDX which did not observe any
genetic alterations in 1 212 cancer-associated genes after two
passages.21 Furthermore in a study of adult DLBCL PDXs, a
comparison of the mutant allele fraction in primary speci-
mens and the associated PDXs indicated that these models
retained the complex genetic signature of primary samples.17
Analysis of the MYC translocation between subsequent
passages from P1 onwards in our PDXs showed maintenance
of the translocation in all cells at P5. Furthermore, the coeffi-
cient of determination for gene expression levels between P1
and P5 was greater than 094 for all five PDXs. At the cellu-
lar level, the histology of each tumour was maintained over
five passages and, significantly, the heterogeneous surface
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protein expression profile was also highly conserved, high-
lighting the potential importance of a tightly controlled pop-
ulation equilibrium within the tumours. Following initial
engraftment these PDX models consistently produce large
tumours within 4-–6 weeks and provide an excellent resource
to investigate the functional significance of tumour hetero-
geneity. The response of each PDX to doxorubicin,
methotrexate and vincristine, components of the LMB
chemotherapeutic backbone for paediatric BL patients, is also
encouraging and highlights that they can be used to model
therapy response and perhaps to elucidate causes of resis-
tance. Of note, differential sensitivity to chemotherapy was
observed among PDXs in this study, highlighting the impor-
tance of intertumour heterogeneity in evaluating treatment
response and the need for personalised medicine approaches.
In summary, we describe in the largest cohort of BL PDX,
based on phenotypical and in-depth molecular characterisation,
the persistence of BL characteristics upon serial passaging in
mice. These PDX models provide a valuable resource to investi-
gate the functional and clinical significance of the heterogenous
populations in BL. These models may be used to elucidate
mechanisms of resistance and relapse so we can ultimately
improve the dismal prognosis for this patient population.
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